Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · Document series

Draft indication set and anchor outcomes

Consultation on the set of indications the Institute assesses against and the anchor outcome defined for each. The draft fixes one anchor outcome per indication so that estimates carried in different documents are estimates of the same quantity, and records…

Document identifier
CEI-CP-024
Series
Public comment period
Version
1.0
Published
08 Oct 2023
Last reviewed
08 Oct 2023
Next review
08 Oct 2024
Identifier
10.71829/cei.cp.24
Certainty
Not rated
Cycle
2023 Q3
Window
09 Aug 2023 – 23 Sep 2023
Status
Closed
Submissions
15

§1Consultation and window

§1.1Window

Opened
9 August 2023
Closed
23 September 2023
Duration
45 days
Status
Closed — the disposition is published
Document under consultation
Document series
Submissions received
15

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

  1. Is the anchor outcome selected for each indication the outcome a decision would actually turn on?
  2. Should a surrogate outcome ever serve as an anchor, and if so under what recorded conditions?
  3. Are any indications missing from the set that the Institute should be assessing against?

§1.3How a submission is handled

  • Every submission is signed. The Institute publishes no anonymous submission.
  • Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
  • A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
  • Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
  • There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

The indication set was ratified with amendments. Two anchor outcomes were changed, a surrogate anchor is now permitted only where the document records the validation evidence for the surrogate, and three indications were added.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.